Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00125788
Recruitment Status : Completed
First Posted : August 2, 2005
Results First Posted : January 29, 2021
Last Update Posted : January 29, 2021
Sponsor:
Collaborator:
FDA Office of Orphan Products Development
Information provided by (Responsible Party):
Emmaus Medical, Inc.

Brief Summary:
The purpose of this research is to evaluate the effects of L-glutamine as a therapy for sickle cell anemia and sickle ß0-thalassemia. as evaluated by the number of occurrences of sickle cell crises.

Condition or disease Intervention/treatment Phase
Sickle Cell Anemia Thalassemia Drug: L-glutamine Drug: Placebo Phase 2

Detailed Description:

The primary purpose of this study is to evaluate the effectiveness of oral L-glutamine in the therapy of sickle cell anemia and sickle ß0-thalassemia.

The secondary purpose is to assess the effect of L-glutamine frequency of hospitalizations for sickle cell pain, frequency of emergency room visits for sickle cell pain; energy and appetite levels; narcotics usage.

Methodology:

By site, patients will be randomized to L-glutamine or placebo in a 1:1 ratio after a 4-week screening period. Patients will undergo 48 weeks of treatment with dosing BID orally, with dose calculated according to patient weight. Patient visits will occur every 4 weeks. After 48 weeks of treatment, dose will be tapered to zero within 3 weeks. A final evaluation visit will occur 2 weeks after last dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Prospective, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of L Glutamine Therapy for Sickle Cell Anemia and Sickle ß0-Thalassemia
Study Start Date : March 2004
Actual Primary Completion Date : July 2008
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Anemia Thalassemia
Drug Information available for: Glutamine

Arm Intervention/treatment
Experimental: investigational product
L-glutamine
Drug: L-glutamine
Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Other Name: oral L-glutamine

Placebo Comparator: placebo
maltodextrin
Drug: Placebo
Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
Other Name: maltodextrin




Primary Outcome Measures :
  1. Number of Occurrences of Painful Sickle Cell Crises [ Time Frame: From Week 0 through Week 48 (cumulative) ]
    The mean number of painful sickle crisis through week 48


Secondary Outcome Measures :
  1. Frequency of Hospitalizations for Sickle Cell Pain [ Time Frame: From Week 0 through Week 48 (cumulative) ]
    The mean number of hospitalizations through week 48

  2. Frequency of Emergency Room Visits for Sickle Cell Pain [ Time Frame: From Week 0 through Week 48 (cumulative) ]
    The mean number of emergency room visits through week 48

  3. The Effect of Oral L-glutamine on Hematological Parameters - Hemoglobin [ Time Frame: Baseline, Weeks 4, 24 and 40 ]
    Patient's hemoglobin will be collected at each visit.Change from Baseline will be reported at Weeks 4, 24 and 40.

  4. The Effect of Oral L-glutamine on Hematological Parameters - Hematocrit [ Time Frame: Baseline, Weeks 4, 24, and 40 ]
    Patient's hematocrit will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24 and 40

  5. The Effect of Oral L-glutamine on Hematological Parameters - Reticulocyte Count [ Time Frame: Baseline, Weeks 0, 4, 24, 40 ]
    Patient's reticulocyte count will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24 and 40

  6. Number of Participants With Narcotic Usage [ Time Frame: Week 24, Week 48 ]
    Analysis of narcotic usage was performed for the subset of patients with any narcotic use who completed the study. Changes in narcotic usage were determined by an independent consultant prior to database lock using morphine equivalents to determine relative use.

  7. Energy Level (11-point Scale) [ Time Frame: Collected at Week 0, 8, 16, 24, 32, 40, 48 ]
    The patient's energy level was evaluated at each visit using an 11 point scale from 0=extremely tired to 10=extremely energetic

  8. Patient Appetite (3-point Scale) [ Time Frame: Collected at Week 0, 8, 16, 24, 32, 40, 48 ]
    Patient's appetite level was evaluated at each visit using a 3 point scale: above average, average and below average. The parentages of patient at each visit whose appetite level was below, normal or above average were compared using CMH test (row mean scores) controlling for study center.

  9. The Effect of Oral L-glutamine on Vital Signs - Blood Pressure [ Time Frame: Baseline, Weeks 4, 24, and 48 ]
    Patient's blood pressure will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48

  10. The Effect of Oral L-glutamine on Vital Signs - Temperature [ Time Frame: Baseline, Weeks 4, 24, and 48 ]
    Patient's temperature will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48

  11. The Effect of Oral L-glutamine on Vital Signs - Respiration [ Time Frame: Baseline, Weeks 4, 24, and 48 ]
    Respiration will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48

  12. The Effect of Oral L-glutamine on Vital Signs - Pulse Rate [ Time Frame: Baseline, Weeks 4, 24, and 48 ]
    Patient's pulse rate will be collected at each visit, Change from Baseline will be reported at Weeks 4, 24, and 48

  13. Effect of L-glutamine on Alcohol Use [ Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48 ]
    The patient's alcohol usage will be assessed at each visit. Alcohol usage will be reported at Weeks 0, 8,16, 24, 32, 40 and 48

  14. Effect of L-glutamine on Tobacco Use [ Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48 ]
    Patient's alcohol usage will be assessed at each visit. Alcohol usage will be reported at Weeks 0, 8,16, 24, 32, 40 and 48

  15. The Effect of Oral L-glutamine on the Number of Days Patient's Daily Activities Are Interrupted Due to Sickle Cell Pain [ Time Frame: Weeks 0, 8,16, 24, 32, 40 and 48 ]
    Percentage of days a patient's daily activities were interrupted due to sickle pain calculated at each visit. Day's interrupted will be reported at Weeks 0, 8,16, 24, 32, 40 and 48

  16. The Effect of Oral L-glutamine on Subjective Quality of Life [ Time Frame: Baseline and Week 24 (or at time of discontinuation) ]
    The subjective quality of life was evaluated using the scoring of the RAND 36-Item Health Survey Questionnaire. The subjective quality of life (Physical functioning, Physical health, Emotional problems, Energy/Fatigue, Emotional well being, Social functioning, Pain, General health) will be reported at Baseline and Week 24 (or at time of discontinuation). The range for Physical functioning, Physical health, Emotional problems, Emotional well being and Social functioning is 0-100, with a high score denotes a better quality of life. For Energy/Fatigue, Pain and General health the range is 0-100, with a lower score denotes better quality of life.

  17. Effect of Oral L--glutamine on Height [ Time Frame: Baseline, Weeks 4, 24, and 48 ]
    Height will be measured at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48

  18. Effect of Oral L--glutamine on Weight [ Time Frame: Baseline, Weeks 4, 24 and 48 ]
    Weight will be measured at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48

  19. Effect of L-glutamine on Subjective Exercise Tolerance - Minutes Patient Could Walk Without Rest [ Time Frame: Baseline, Weeks 4, 24, and 48. ]
    Minutes patient could walk without rest will be measured at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48.

  20. Effect of L-glutamine on Subjective Exercise Tolerance - Minutes Patient Could Run Without Rest [ Time Frame: Baseline, Weeks 4, 24, and 48. ]
    Minutes patient could run without rest will be measured at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48.

  21. Effect of L-glutamine on Subjective Exercise Tolerance - Distance Patient Could Walk Without Rest [ Time Frame: Baseline, Weeks 4, 24, and 48. ]
    Distance patient could walk without rest will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48.

  22. Effect of L-glutamine on Subjective Exercise Tolerance - Distance Patient Could Run Without Rest [ Time Frame: Baseline, Weeks 4, 24, and 48. ]
    Distance patient could run without rest will be collected at each visit. Change from Baseline will be reported at Weeks 4, 24, and 48.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

To be eligible to participate in the study, a patient must meet all of the following inclusion criteria:

  • Patient is at least five years of age.
  • Patient has been diagnosed with sickle cell anemia or sickle ß0-thalassemia (documented by hemoglobin electrophoresis).
  • Patient has had at least two episodes of painful crises within 12 months of the screening visit.
  • If the patient has been treated with an anti-sickling agent within three months of the screening visit, the therapy must have been continuous for at least three months with the intent to continue for the next 14 months.
  • Patient or the patient's legally authorized representative has given written informed consent.
  • If the patient is a female of child-bearing potential, she agrees to practice a recognized form of birth control during the course of the study.

Exclusion Criteria:

If the patient meets any of the following criteria, the patient must not be enrolled:

  • Patient has a significant medical condition that required hospitalization (other than sickle painful crisis) within two months of the screening visit.
  • Patient has diabetes mellitus with untreated fasting blood sugar >115 mg/dL.
  • Patient has prothrombin time International Normalized Ratio (INR) > 2.0.
  • Patient has serum albumin < 3.0 g/dl.
  • Patient has received any blood products within three weeks of the screening visit.
  • Patient has a history of uncontrolled liver disease or renal insufficiency.
  • Patient is pregnant or lactating.
  • Patient has been treated with an experimental anti-sickling medication/treatment (except hydroxyurea) within 30 days of the screening visit.
  • Patient has been treated with an experimental drug within 30 days of the screening visit.
  • There are factors that would, in the judgment of the investigator, make it difficult for the patient to comply with the requirements of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00125788


Locations
Layout table for location information
United States, California
Kaiser Permanente
Bellflower, California, United States, 90706
Harbor-UCLA Medical Center
Torrance, California, United States, 90502
United States, Georgia
Grady Memorial Hospital
Atlanta, Georgia, United States, 30303
United States, New Jersey
University of Medicine and Dentistry, New Jersey
New Brunswick, New Jersey, United States, 08903
United States, New York
Jacobi Medical Center
Bronx, New York, United States, 10461
Sponsors and Collaborators
Emmaus Medical, Inc.
FDA Office of Orphan Products Development
Investigators
Layout table for investigator information
Principal Investigator: Yutaka Niihara, MD CEO, Emmaus Medical, Inc
Layout table for additonal information
Responsible Party: Emmaus Medical, Inc.
ClinicalTrials.gov Identifier: NCT00125788    
Obsolete Identifiers: NCT00029887
Other Study ID Numbers: 10478
First Posted: August 2, 2005    Key Record Dates
Results First Posted: January 29, 2021
Last Update Posted: January 29, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Emmaus Medical, Inc.:
sickle cell disease
sickle cell anemia
L-glutamine
Sickle Cell Anemia (homozygous)
Sickle ß0-Thalassemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Anemia
Thalassemia
Anemia, Sickle Cell
Hematologic Diseases
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Hemoglobinopathies
Genetic Diseases, Inborn